Key Takeaways
- • The One Big Beautiful Bill Act (OBBBA) permanently restores 100% bonus depreciation for qualified capital asset purchases, effective in 2025 and all future tax years, eliminating the historical expiration-and-renewal cycle that previously constrained business investment planning.
- • Domestic R&D expense deductions are now fully deductible in the year incurred on a permanent basis beginning 2025, while foreign R&D remains subject to 15-year amortization, creating a structural incentive favoring domestic research investment.
- • Qualified small businesses can retroactively apply full expensing to R&D costs from 2022-2024 that were previously required to be amortized, allowing amended tax returns to accelerate deductions and improve near-term cash position.
- • The R&D tax credit for eligible costs increases from 25% to 40% starting 2026, with the maximum allowable credit jumping to $500,000—a material expansion for technology companies and innovation-focused enterprises.
- • The 20% Qualified Business Income (QBI) deduction is made permanent, with enhanced phase-out thresholds beginning 2026, and the Tax Foundation estimates the law will increase after-tax incomes by 5.4% in 2026 and 3.6% in 2034 on a dynamic basis.
Summary
The One Big Beautiful Bill Act represents a comprehensive restructuring of business tax incentives with particular emphasis on permanent rather than temporary relief measures. The legislation's most significant provisions for capital-intensive and research-driven businesses center on two core mechanics: immediate expensing of equipment and infrastructure, and full deductibility of domestic research and development costs.
Permanent 100% bonus depreciation—first introduced in 2001 and subject to repeated congressional extensions and expirations—is now codified as a permanent feature of the tax code. This eliminates temporal uncertainty that previously forced businesses to time capital expenditures around depreciation schedules. Businesses can now immediately deduct the full cost of qualifying asset purchases in 2025 and all subsequent tax years without legislative risk. This provision is particularly material for infrastructure, manufacturing, and technology sectors where capital investments often span multiyear planning horizons.
The OBBBA's R&D provisions deliver dual benefits. Effective 2025, qualified domestic R&D expenditures are now fully deductible in the year incurred, reversing the 15-year amortization requirement that had constrained tech companies and life sciences firms. Foreign R&D spending remains subject to 15-year amortization, creating a structural preference for domestic research concentration. Critically, the legislation permits retroactive application: qualified small businesses can amend 2024, 2023, and 2022 tax returns to immediately expense R&D costs that were previously being amortized, accelerating cash recovery across multiple prior years.
Beginning 2026, the R&D tax credit rate increases to 40% of eligible costs (from 25%), with the annual credit maximum rising to $500,000. This amplification directly benefits technology, pharmaceutical, and advanced manufacturing firms with substantial research programs. Simultaneously, the 20% Qualified Business Income (QBI) deduction—originally set to expire at year-end 2025—is now permanent, with improved phase-out thresholds for specified service trades and businesses (SSTBs) taking effect in 2026.
According to the Tax Foundation's distributional analysis, the cumulative effect is projected to increase after-tax incomes by 5.4% in 2026 and 3.6% in 2034 on a dynamic basis. Middle-income quintiles realize the largest proportional gains in 2026 due to the combination of extended TCJA provisions and targeted credits. These provisions collectively reduce the after-tax cost of capital expenditure and research investment, incentivizing domestic business expansion and innovation activity.
Permanent 100% bonus depreciation—first introduced in 2001 and subject to repeated congressional extensions and expirations—is now codified as a permanent feature of the tax code. This eliminates temporal uncertainty that previously forced businesses to time capital expenditures around depreciation schedules. Businesses can now immediately deduct the full cost of qualifying asset purchases in 2025 and all subsequent tax years without legislative risk. This provision is particularly material for infrastructure, manufacturing, and technology sectors where capital investments often span multiyear planning horizons.
The OBBBA's R&D provisions deliver dual benefits. Effective 2025, qualified domestic R&D expenditures are now fully deductible in the year incurred, reversing the 15-year amortization requirement that had constrained tech companies and life sciences firms. Foreign R&D spending remains subject to 15-year amortization, creating a structural preference for domestic research concentration. Critically, the legislation permits retroactive application: qualified small businesses can amend 2024, 2023, and 2022 tax returns to immediately expense R&D costs that were previously being amortized, accelerating cash recovery across multiple prior years.
Beginning 2026, the R&D tax credit rate increases to 40% of eligible costs (from 25%), with the annual credit maximum rising to $500,000. This amplification directly benefits technology, pharmaceutical, and advanced manufacturing firms with substantial research programs. Simultaneously, the 20% Qualified Business Income (QBI) deduction—originally set to expire at year-end 2025—is now permanent, with improved phase-out thresholds for specified service trades and businesses (SSTBs) taking effect in 2026.
According to the Tax Foundation's distributional analysis, the cumulative effect is projected to increase after-tax incomes by 5.4% in 2026 and 3.6% in 2034 on a dynamic basis. Middle-income quintiles realize the largest proportional gains in 2026 due to the combination of extended TCJA provisions and targeted credits. These provisions collectively reduce the after-tax cost of capital expenditure and research investment, incentivizing domestic business expansion and innovation activity.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.